Nevro Corporation has announced that two abstracts for clinical trials relating to painful diabetic neuropathy (PDN) and non-surgical back pain (NSBP) treatments have been accepted as podium presentations at the upcoming North American Neuromodulation Society (NANS) annual meeting (12–15 January 2023, Las Vegas, USA).
A total of 18 abstracts covering Nevro’s proprietary 10kHz therapy were accepted for presentation at NANS 2023, including seven podium presentations and nine posters as well as the aforementioned late-breakers.
The company’s presentation of new PDN data—entitled ‘10kHz SCS Provides Durable Pain Relief for Patients with Painful Diabetic Neuropathy’—will highlight complete 24-month follow-up results for pain relief and improved neurological function in the SENZA-PDN trial.
According to Nevro, this is the largest Level 1 randomised controlled trial (RCT) studying a spinal cord stimulation (SCS) treatment for PDN that has been completed to date, with 216 randomised subjects. Late-breaking SENZA-PDN results will be presented by Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, USA) on 14 January.
A second PDN data presentation, entitled ‘10kHz SCS Significantly Improves Health-Related Quality of Life for Patients with Painful Diabetic Neuropathy’, will feature results showing improvements in multiple quality of life metrics with 10kHz therapy. These results will also be presented by Petersen on 13 January.
Nevro’s key NSBP data presentation, entitled ‘Treating Non-surgical Refractory Back Pain with 10kHz Spinal Cord Stimulation: 24 Month Follow-up from RCT’, will feature 24-month outcomes from its SENZA-NSRBP RCT investigating 10kHz therapy for treating non-surgical refractory back pain (NSRBP) across 159 randomised participants at 15 study centres. Results from this study will be presented by Leonardo Kapural (Carolinas Pain Institute, Winston-Salem, USA) during the late-breaking abstracts session on 13 January.
A second NSBP data presentation—entitled ‘10kHz Spinal Cord Stimulation for Non-Surgical Refractory Back Pain: Objective Functional Outcome to 24-Months’—will feature improvements in non-pain outcomes, such as sleep, mental health and function, experienced by patients treated with 10kHz therapy in the SENZA-NSRBP RCT. Jessica Jameson (Axis Spine Center, Coeur d’Alene, USA) will present these findings on 13 January.
In addition, a poster presentation, entitled ‘Ten-Year Real-World Data on the Efficacy of High-Frequency 10kHz Spinal Cord Stimulation’, will feature 10-year follow-up data from patients who originally participated in the SENZA EU study and continued with usual care in a real-world setting over a mean period of 10 years. This poster is set to be presented by Jean-Pierre van Buyten (AZ Nikolaas Hospital, Sint-Niklaas, Belgium).
